1. Home
  2. MRSN vs CLIR Comparison

MRSN vs CLIR Comparison

Compare MRSN & CLIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRSN
  • CLIR
  • Stock Information
  • Founded
  • MRSN 2001
  • CLIR 2008
  • Country
  • MRSN United States
  • CLIR United States
  • Employees
  • MRSN N/A
  • CLIR N/A
  • Industry
  • MRSN Biotechnology: Pharmaceutical Preparations
  • CLIR Industrial Machinery/Components
  • Sector
  • MRSN Health Care
  • CLIR Industrials
  • Exchange
  • MRSN Nasdaq
  • CLIR Nasdaq
  • Market Cap
  • MRSN 40.7M
  • CLIR 35.6M
  • IPO Year
  • MRSN 2017
  • CLIR 2012
  • Fundamental
  • Price
  • MRSN $0.36
  • CLIR $0.62
  • Analyst Decision
  • MRSN Strong Buy
  • CLIR Strong Buy
  • Analyst Count
  • MRSN 5
  • CLIR 1
  • Target Price
  • MRSN $5.75
  • CLIR $2.00
  • AVG Volume (30 Days)
  • MRSN 2.3M
  • CLIR 52.0K
  • Earning Date
  • MRSN 08-12-2025
  • CLIR 08-13-2025
  • Dividend Yield
  • MRSN N/A
  • CLIR N/A
  • EPS Growth
  • MRSN N/A
  • CLIR N/A
  • EPS
  • MRSN N/A
  • CLIR N/A
  • Revenue
  • MRSN $34,006,000.00
  • CLIR $2,895,000.00
  • Revenue This Year
  • MRSN N/A
  • CLIR $27.61
  • Revenue Next Year
  • MRSN $1.30
  • CLIR $116.19
  • P/E Ratio
  • MRSN N/A
  • CLIR N/A
  • Revenue Growth
  • MRSN N/A
  • CLIR 10.88
  • 52 Week Low
  • MRSN $0.26
  • CLIR $0.46
  • 52 Week High
  • MRSN $2.83
  • CLIR $1.72
  • Technical
  • Relative Strength Index (RSI)
  • MRSN 46.82
  • CLIR 49.24
  • Support Level
  • MRSN $0.35
  • CLIR $0.57
  • Resistance Level
  • MRSN $0.39
  • CLIR $0.66
  • Average True Range (ATR)
  • MRSN 0.03
  • CLIR 0.06
  • MACD
  • MRSN -0.00
  • CLIR -0.00
  • Stochastic Oscillator
  • MRSN 12.30
  • CLIR 46.93

About MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

About CLIR ClearSign Technologies Corporation (DE)

ClearSign Technologies Corp is engaged in providing solutions to some of the pressing productivity, energy efficiency, and pollution problems affecting the energy, oil, and gas production, boiler, and processing industries. It believes that its patented ClearSign Core technology can enhance the performance of combustion systems in a broad range of markets, including the energy (upstream oil production and downstream refining), institutional, commercial, and industrial boiler, chemical, and petrochemical industries. The company offers products that include process burners, boiler burners, flares, and ClearSign Eye.

Share on Social Networks: